Compare MBBC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MBBC | BOLD |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 36.5M |
| IPO Year | N/A | 2024 |
| Metric | MBBC | BOLD |
|---|---|---|
| Price | $13.76 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 12.0K | ★ 407.5K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $47.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.94 | $0.96 |
| 52 Week High | $14.64 | $1.78 |
| Indicator | MBBC | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 62.14 |
| Support Level | $12.93 | $1.08 |
| Resistance Level | N/A | $1.55 |
| Average True Range (ATR) | 0.41 | 0.09 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 99.47 | 66.96 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.